New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
06:49 EDTSCMPSucampo to present data for lubiprostone
Sucampo Pharmaceuticals announced that clinical data for lubiprostone will be presented at the American Pain Society Conference in Tampa, Florida and Digestive Disease Week, or DDW, 2014 in Chicago, Illinois. Posters include: efficacy of lubiprostone for the treatment of opioid-induced constipation according to opioid class Poster 452; Lubiprostone for Treatment of Opioid-Induced Constipation: Analysis of Response by Opioid Class; a Pooled Analysis of Response to Lubiprostone in Patients With Opioid-Induced Constipation Receiving Non-Methadone Opioids Versus Methadone; nausea Reported by Patients Enrolled in Clinical Studies of Lubiprostone: Analysis of Well-Controlled and Long-Term, Open-Label Studies of Chronic Idiopathic Constipation, Opioid-Induced Constipation, and Irritable Bowel Syndrome With Constipation; the CIC-2 chloride channel activator, lubiprostone, prevents ileal epithelial permeability alterations in a murine model of diarrhea-predominant irritable bowel syndrome.
News For SCMP From The Last 14 Days
Check below for free stories on SCMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
16:40 EDTSCMPSucampo announces exclusive manufacturing, supply agreement for Lubiprostone
Sucampo Pharmaceuticals (SCMP) announced that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement, or EMSA, with its manufacturing and development partner, R-Tech Ueno, for clinical and commercial supplies of AMITIZA, or lubiprostone, in most global markets. Under the new EMSA, Sucampo receives a new, lower price for certain components of or finished product of lubiprostone globally, except for the U.S. and Canada until the collaboration and license agreement with Takeda Pharmaceutical Company (TKPYY), expires in December 31, 2020, and except for Japan until the manufacturing and supply agreement for Japan expires or certain material circumstances occur. Additionally, under the EMSA Sucampo has the right to qualify a back-up supplier for lubiprostone in expanded circumstances, such as an authorized generic, additional formulations, and/or inability to supply product in certain circumstances, among others. The new EMSA supersedes the current manufacturing and supply agreements with R-Tech except in those situations noted above and is effective as of January 1.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use